Every Form 4 that Immix Biopharma Inc (IMMX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMMX filings page.
Immix Biopharma director Helen C. Adams received new equity awards as part of her compensation. She was granted 6,250 restricted stock units of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual shareholder meeting, subject to her continued service.
Adams was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. These options vest in substantially equal monthly installments over 12 months following the grant date, or sooner if the 2027 annual meeting occurs earlier. After the RSU grant, her direct common stock holdings total 181,004 shares.
Immix Biopharma director Carey Ng reported new equity awards and updated holdings. He received 6,250 restricted stock units under the 2021 Equity Incentive Plan, which vest in full on the earlier of the one-year anniversary of grant or the 2027 annual stockholders’ meeting, subject to continued service. He was also granted a stock option for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, with an expiration date in 2036. Following these awards, he directly holds 26,250 common shares and has indirect ownership of 1,025,221 shares through Mesa Verde Venture Partners III, LP, where he has voting and disposition power but disclaims beneficial ownership except for his pecuniary interest. The filing does not show any open-market purchases or sales.
Immix Biopharma director Magda Marquet reported new equity awards in the form of restricted stock units and stock options. On May 22, 2026, she was granted 6,250 restricted stock units under the company’s 2021 Equity Incentive Plan and 12,500 stock options with an exercise price of $8.78 per share.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix Biopharma’s 2027 annual stockholder meeting, subject to continued service. The stock options vest in substantially equal monthly installments over 12 months, or fully on the 2027 annual meeting date if it occurs earlier, also subject to her continued board service.
Following these awards, Marquet directly holds 52,342 shares of common stock and 12,500 stock options, and is associated with 20,000 additional shares held indirectly by Alma Life Sciences, LLC, for which she disclaims beneficial ownership beyond any pecuniary interest.
Immix Biopharma, Inc. reported that its CFO and President, Morris Gabriel S, received a grant of stock options covering 500,000 shares of Common Stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036. The award vests in 48 equal monthly installments after the grant date, tying the executive’s potential ownership to continued service with the company.
Immix Biopharma director Nancy T. Chang reported new equity awards, not open‑market trades. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, which vest in full on the earlier of the one-year anniversary of grant or the company’s 2027 annual stockholders’ meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036, vesting in substantially equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, she holds 428,190 common shares directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and disclaims beneficial ownership except for her pecuniary interest.
Immix Biopharma, Inc. reported that CEO and Chairman Ilya M. Rachman received a grant of stock options covering 500,000 shares of common stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036.
These options were granted as compensation and do not represent an open-market purchase or sale. According to the terms, they vest in 48 equal monthly installments following the grant date, contingent on Dr. Rachman’s continued service with the company.
Immix Biopharma director Yekaterina Chudnovsky reported equity awards and updated holdings. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, vesting in full on the earlier of one year from grant or the 2027 annual stockholders meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, contingent on continued board service. Following this Form 4, she holds 6,250 common shares directly and 12,500 options, and is associated with 3,241,076 shares held indirectly by GKCC, LLC, where she is the sole member and manager.
Hsu Jason reported acquisition or exercise transactions in this Form 4 filing.
Immix Biopharma, Inc. director Jason Hsu reported new equity compensation. He received 6,250 restricted stock units that vest in full on the earlier of one year from grant or the company’s 2027 annual meeting, subject to continued service. He was also granted a stock option for 12,500 shares at $8.78 per share, vesting in equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, he holds 899,250 common shares directly, plus additional indirect holdings through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, where he has voting and disposition rights but disclaims beneficial ownership except for his pecuniary interest.
Immix Biopharma director Jane Buchan reported equity compensation awards. She received 6,250 restricted stock units of common stock, bringing her direct common stock holdings to 28,705 shares after the grant.
She was also granted options to buy 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. The RSUs vest in full on the earlier of one year from grant or the 2027 annual meeting, while the options vest in substantially equal monthly installments over 12 months, with any remaining portion vesting at the 2027 annual meeting, in each case subject to continued service.
Immix Biopharma director Dr. Nancy T. Chang reported an equity award dated 11/21/2025. She received a stock option (right to buy common stock) for 39,643 shares at an exercise price of $4.33 per share, exercisable until 11/21/2035.
The option will vest in 36 equal monthly installments following the grant date, subject to her continued service and a stock option agreement. After the reported transaction, she beneficially owned 421,940 shares of common stock directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and may be deemed to beneficially own those securities while disclaiming ownership beyond her pecuniary interest.
Immix Biopharma insider purchase by CEO/Chairman — This Form 4 shows that Ilya M. Rachman, who is identified as a director and as the CEO and Chairman of Immix Biopharma, Inc. (IMMX), purchased 2,500 shares of the company on 09/17/2025 at a volume-weighted average price of $2.02 per share. After the purchase, the filing reports that Mr. Rachman beneficially owned 1,140,937 shares. The filing includes an explanation that the $2.02 VWAP reflects purchases executed at prices ranging from $2.01 to $2.02 and offers to provide transaction-level detail on request. The form is signed by the reporting person on 09/17/2025.
Immix Biopharma insider purchase: Gabriel Morris, reporting as a Director and CFO, purchased 2,600 shares of Immix Biopharma, Inc. (IMMX) on 09/16/2025 at a price of $1.97 per share. After the transaction he reports 290,659 shares directly beneficially owned and additional indirect holdings of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures/AVILP, with footnotes clarifying his managerial roles and disclaimer of beneficial ownership except for pecuniary interest. The Form 4 is signed by Gabriel Morris on 09/17/2025.